The efficiency of combinations of Enalapril and long-acting Nifedipin and Moxonidine in patients with arterial hypertension and a metabolic syndrome

• Published in: Klinicheskaia meditsina Vol. 86; no. 7; p. 56
• Main Authors: Mananko, E I, Vorob'eva, E V, Kalashnikova, T P, Bushkova, E A, Krasnova, N M, Idrisova, E M, Vengerovskiĭ, A I, Karpov, R S, Gruzdeva, O V, Kremenko, S V
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2008
• Subjects: Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Blood Glucose - metabolism; Blood Pressure - physiology; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers - therapeutic use; Delayed-Action Preparations; Drug Therapy, Combination; Enalapril - therapeutic use; Female; Follow-Up Studies; Humans; Hypertension - complications; Hypertension - drug therapy; Hypertension - physiopathology; Male; Metabolic Syndrome - blood; Metabolic Syndrome - complications; Metabolic Syndrome - drug therapy; Middle Aged; Nifedipine - therapeutic use; Treatment Outcome
• ISSN: 0023-2149

The aim of the study was to obtain a comparative evaluation of antihypertensive efficacy, tolerability and influence of combine therapy on myocardium mass, diastolic function of a left ventricle, lipid and carbohydrate exchange in patients with arterial hypertension in metabolic syndrome. Out of 40 examined cases 20 patients took enalapril and long-acting nifedipin and 20 ones--enalapril and moxonidine. All examination were been performed before administration of drugs and 6 months after the therapy. The dynamics of indices of ambulatory blood pressure monitoring, echocardiography, cycle ergometry, anthropometry, lipid, carbohydrate exchange and tolerability of conducted therapy was been evaluated. The use of this combination of the drugs may be recommended to be included in the treatment of arterial hypertension within the bounds of metabolic syndrome, as in most of cases they promote an achievement of target blood pressure level, have a cardioprotective action, high tolerability and favorable metabolic profile. The combination of enalapril and long-acting nifedipin has a more evident antihypertensive activity but a therapy with enalapril and moxonidine has a positive effect on the indices of carbohydrate exchange.